Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Patent
1993-11-08
1997-09-16
Goldberg, Jerome D.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
A61K 3135
Patent
active
056681712
ABSTRACT:
Compositions that include as an active ingredient an effective concentration of a halogenated mevalonate preparation, particularly, Fmev (fluoromevalonate) are provided. The pharmacological activity of halogenated mevalonate for inhibiting ras-dependent cell growth, particularly ras-dependent tumor cell growth, is described. Methods for using preparations including a therapeutically effective concentration of Fmev for the inhibition of ras-dependent cell growth, as well as in the treatment and inhibition of ras-dependent tumors is also disclosed. The claimed compositions may be provided in liquid, salve, tablet, or capsule form, as well as other forms suitable for administration to an animal.
REFERENCES:
patent: 5244916 (1993-09-01), Bokoch
Bos, J.L., The ras gene family and human carcinogenesis, Mutation Research, 195: 255-271, 1988.
Cuthbert, J.A. and Lipsky, P.E., Selective supression of activated p21ras-dependent proliferation by fluoromevalonate, Abstract No. BZ 403, Journal of Cellular Biochemistry, 17(A), Suppl., p. 279, Jan. 1993.
Cuthbert, J.A. and Lipsky, P.E., Negative Regulation of Cell Proliferation by Mevalonate or One of the Mevalonate Phosphates, J. Biol. Chem., 266: (27) 17966-17971, 1991.
Cuthbert, J.A. and Lipsky, P.E., Inhibition by 6-Fluoromevalonate Demonstrates That Mevalonate or One of the Mevalonte Phosphates is Necessary for Lymphoctye Proliferation, J. Biol. Chem., 265: (30) 18568-18575, 1990.
Quistad, et al., Fluoromevalonate --an inhibitor of insect juvenile hormone biosynthesis, Scientific Papers of the Institute of Organic and Physical Chemistry of Wroclaw Technical University, No. 22, Conferences 7, 163-168, 1981.
Reardon, J.E. and Abeles, R.H., Inhibition of cholesterol biosynthesis by fluorinated mevalonate analogues, Biochemistry, 26: 4717-4722, 1987.
Conley and Van Echo, "Antineoplastic Drug Development," The Chemotherapy Source Book, Principles of Chemotherapy, Section One, Michael C. Perry, Ed., Williams & Wilkins, Baltimore, MD, Publishers, pp. 15-21, 1992.
Gibbs, Jackson B., "Ras C-Terminal Processing Enzymes-New Drug Targets?" Cell, 65:1-4, 1991.
Hagg et al., "Limonene-Induced Regression of Mammary Carcinomas," Cancer Research, 52:4021-4026, 1992.
Hara et al., "Identification of Ras Farnesyltransferase Inhibitors by Microbial Screening," Proc. Natl. Acad. Sci. USA, 90:2281-2285, 1993.
Rodent Tumor Models in Experimental Cancer Therapy, Robert F. Kallman, Ed., Pergamon Press, Elmsford, NY, Publishers, Table of Contents, pp. v-ix, 1987.
Kohl et al., "Protein Farnesyltransferase Inhibitors Block the Growth of ras-dependent Tumors in Nude Mice," Proc. Natl. Acad. Sci., 91:9141-9145, 1994.
Miller et al., "Increased Radioresistance of EJras-Transformed Human Osteosarcoma Cells and Its Modulation by Lovastatin, an Inhibitor of p21.sup.ras Isoprenylation", Int. J. Cancer, 53:302-307, 1993.
Moyer and Fischer, "The Promise of Oncogene Inhibitors as Novel Antitumor Agents," Cancer Chemotherapy, Chapter 1, pp. 1-20, John A. Hickman and Thomas R. Tritton, Eds., Blackwell Scientific Publications, Publishers, Boston, MA, 1992.
Ruch et al., "Reversal of ras-Induced Inhibition of Gap-Junctional Intercellular Communication, Transformation, and Tumorigenesis by Lovastatin," Molecular Carcinogenesis, 7:50-59, 1993.
PCT Search Report mailed Aug. 11, 1994.
Leonard et al., "Inhibition of Isoprenoid Biosynthesis and the Post-translational Modification of pro-p21.sup.ras," The Journal of Biological Chemistry, 265(9):5157-5160, 1990.
Cuthbert Jennifer A.
Lipsky Peter E.
Board of Regents , The University of Texas System
Goldberg Jerome D.
Mayfield, Esq. Denise L.
LandOfFree
Halogenated mevalonate compositions and uses thereof in ras-depe does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Halogenated mevalonate compositions and uses thereof in ras-depe, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Halogenated mevalonate compositions and uses thereof in ras-depe will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-218777